Skip to content

Study · Ex vivo tissue · bovine · 2018

4 results

Mitoprotective therapy preserves chondrocyte viability and prevents cartilage degeneration in an ex vivo model of posttraumatic osteoarthritis.

Delco ML, Bonnevie ED, Szeto HS, Bonassar LJ, Fortier LA

Journal of orthopaedic research : official publication of the Orthopaedic Research Society22 Feb 2018Cited by 35 (Europe PMC)

PMID29469223 (opens in a new tab)PMCIDPMC6105558 (opens in a new tab)DOI10.1002/jor.23882 (opens in a new tab)PepBankPUB-29469223
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueEfficacy outcome

    In bovine cartilage explants after impact injury, SS‑31 given up to 12 h after injury kept chondrocyte viability similar to that of un-injured controls, for up to a week.

    In plain wordsIn lab tests on injured cow cartilage, SS‑31 kept cartilage cells alive, at levels like uninjured cartilage, for up to a week.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseChondrocyte viability
    Study

    bovinen: not reported in source

    bovine knee cartilage explants after impact injury
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 µM · up to 7 daysAs given in this study (bovine).

    Source sentences

    Summary
    SS-31 treatment at all time points after impact resulted in chondrocyte viability similar to that of un-injured controls.
    3 context sentences
    Summary · context
    This effect was sustained for up to a week in culture.
    Summary · context
    Cartilage was harvested from bovine knee joints and subjected to a single, rapid impact injury (24.0 ±1.4 MPa, 53.8 ± 5.3 GPa/s).
    Summary · context
    Explants were then treated with a mitoprotective peptide, SS-31 (1µM), immediately post-impact, or at 1, 6, or 12 h after injury, and then cultured for up to 7 days.
  2. 02LabEx vivo tissueEfficacy outcome

    In bovine cartilage explants after impact injury, SS‑31 prevented impact-induced chondrocyte apoptosis.

    In plain wordsIn lab tests on injured cow cartilage, SS‑31 prevented injury-induced death of cartilage cells.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseChondrocyte apoptosis
    Study

    bovinen: not reported in source

    bovine knee cartilage explants after impact injury
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 µM · up to 7 daysAs given in this study (bovine).

    Source sentences

    Summary
    SS-31 prevented impact-induced chondrocyte apoptosis
    2 context sentences
    Summary · context
    Cartilage was harvested from bovine knee joints and subjected to a single, rapid impact injury (24.0 ±1.4 MPa, 53.8 ± 5.3 GPa/s).
    Summary · context
    Explants were then treated with a mitoprotective peptide, SS-31 (1µM), immediately post-impact, or at 1, 6, or 12 h after injury, and then cultured for up to 7 days.
  3. 03LabEx vivo tissueEfficacy outcome

    In bovine cartilage explants after impact injury, SS‑31 prevented impact-induced cell membrane damage.

    In plain wordsIn lab tests on injured cow cartilage, SS‑31 prevented injury-induced damage to cell membranes.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCell membrane damage (lactate dehydrogenase activity)
    Study

    bovinen: not reported in source

    bovine knee cartilage explants after impact injury
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 µM · up to 7 daysAs given in this study (bovine).

    Source sentences

    Summary
    Further, SS-31 prevented impact-induced chondrocyte apoptosis, cell membrane damage, and cartilage matrix degeneration.
    3 context sentences
    Summary · context
    Cell membrane damage (lactate dehydrogenase activity) and cartilage matrix degradation (glycosaminoglycan loss) were quantified in cartilage-conditioned media.
    Summary · context
    Cartilage was harvested from bovine knee joints and subjected to a single, rapid impact injury (24.0 ±1.4 MPa, 53.8 ± 5.3 GPa/s).
    Summary · context
    Explants were then treated with a mitoprotective peptide, SS-31 (1µM), immediately post-impact, or at 1, 6, or 12 h after injury, and then cultured for up to 7 days.
  4. 04LabEx vivo tissueEfficacy outcome

    In bovine cartilage explants after impact injury, SS‑31 prevented impact-induced cartilage matrix degeneration.

    In plain wordsIn lab tests on injured cow cartilage, SS‑31 prevented injury-induced breakdown of the cartilage matrix.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCartilage matrix degeneration (glycosaminoglycan loss)
    Study

    bovinen: not reported in source

    bovine knee cartilage explants after impact injury
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 µM · up to 7 daysAs given in this study (bovine).

    Source sentences

    Summary
    Further, SS-31 prevented impact-induced chondrocyte apoptosis, cell membrane damage, and cartilage matrix degeneration.
    3 context sentences
    Summary · context
    Cell membrane damage (lactate dehydrogenase activity) and cartilage matrix degradation (glycosaminoglycan loss) were quantified in cartilage-conditioned media.
    Summary · context
    Cartilage was harvested from bovine knee joints and subjected to a single, rapid impact injury (24.0 ±1.4 MPa, 53.8 ± 5.3 GPa/s).
    Summary · context
    Explants were then treated with a mitoprotective peptide, SS-31 (1µM), immediately post-impact, or at 1, 6, or 12 h after injury, and then cultured for up to 7 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.